SHH and medulloblastoma: MBEN as well as DNMB must show a SHH activation according to the revised WHO classification 2016 [20]; therefore, immunohistochemistry for SHH target proteins can be used for the differential diagnosis of nodular entities vs. classic medulloblastoma (see below).